How non-small cell lung cancer and the lung environment change during treatment
The Delta Ecology of NSCLC Treatment
This project will track how non-small cell lung cancer tumors and their surrounding lung environment change during targeted treatments for people with NSCLC.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11211079 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers will use existing clinical records and tumor samples to map how cancer cells and nearby tissues evolve while someone is on therapy. They will feed those real-world data into computer models, then test predictions in lab-grown cells and animal models to refine their understanding. The work focuses on tumors with common driver mutations (EGFR, ALK, RAS) and follows a cycle of develop, predict, calibrate, test, optimize, and validate. The team aims to translate these findings into strategies that could change how treatments are timed or combined.
Who could benefit from this research
Good fit: People with non-small cell lung cancer—especially those whose tumors have EGFR, ALK, or RAS driver mutations—are the most relevant candidates for involvement or to benefit from this work.
Not a fit: People without NSCLC or whose tumors lack these targetable driver mutations are unlikely to be directly helped by this project.
Why it matters
Potential benefit: If successful, this work could help tailor treatments to delay or prevent drug resistance and improve outcomes for people with NSCLC.
How similar studies have performed: Combining clinical data, mathematical models, and lab validation has shown promise in cancer research, but this integrated, mutation-specific center approach is relatively novel.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Anderson, Alexander Robertson Allan — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Anderson, Alexander Robertson Allan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.